Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 3Interventional 3Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 2Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neurofibromatoses 1Neurofibroma, Plexiform 1Melanoma 1Mastocytosis, Systemic 1Leukemia, Mast-Cell 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Desmoid Tumors 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Neurofibromatoses × 30 days × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡